Trials / Active Not Recruiting
Active Not RecruitingNCT06431373
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 371 (actual)
- Sponsor
- Priovant Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brepocitinib PO QD | Brepocitinib PO QD |
| DRUG | Placebo PO QD | Placebo PO QD |
Timeline
- Start date
- 2024-09-11
- Primary completion
- 2026-09-11
- Completion
- 2028-02-01
- First posted
- 2024-05-28
- Last updated
- 2026-01-12
Locations
107 sites across 13 countries: United States, Argentina, Australia, Austria, Belgium, Czechia, Germany, Greece, Hungary, Israel, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06431373. Inclusion in this directory is not an endorsement.